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Intravital imagingMacrophages are innate immune cellswith great phenotypic plasticity,which allows them to regulate an array of
physiological processes such as host defense, tissue repair, and lipid/lipoprotein metabolism. In this proof-of-
principle study, we report that macrophages of the M1 inﬂammatory phenotype can be selectively targeted by
model hybrid lipid–latex (LiLa) nanoparticles bearing phagocytic signals. We demonstrate a simple and robust
route to fabricate nanoparticles and then show their efﬁcacy through imaging and drug delivery in inﬂammatory
diseasemodels of atherosclerosis and obesity. Self-assembled LiLa nanoparticles can bemodiﬁedwith a variety of
hydrophobic entities such as drug cargos, signaling lipids, and imaging reporters resulting in sub-100 nm nano-
particles with low polydispersities. The optimized theranostic LiLa formulation with gadolinium, ﬂuorescein and
“eat-me” phagocytic signals (Gd-FITC-LiLa) a) demonstrates high relaxivity that improves magnetic resonance
imaging (MRI) sensitivity, b) encapsulates hydrophobic drugs at up to 60% by weight, and c) selectively targets
inﬂammatory M1 macrophages concomitant with controlled release of the payload of anti-inﬂammatory drug.
The mechanism and kinetics of the payload discharge appeared to be phospholipase A2 activity-dependent, as
determined by means of intracellular Förster resonance energy transfer (FRET). In vivo, LiLa targets M1 macro-
phages in a mouse model of atherosclerosis, allowing noninvasive imaging of atherosclerotic plaque by MRI. In
the context of obesity, LiLa particles were selectively deposited to M1 macrophages within inﬂamed adipose
tissue, as demonstrated by single-photon intravital imaging inmice. Collectively, our results suggest that phago-
cytic signals can preferentially target inﬂammatory macrophages in experimental models of atherosclerosis and
obesity, thus opening the possibility of future clinical applications that diagnose/treat these conditions. Tunable
LiLa nanoparticles reported here can serve as a model theranostic platform with application in various types of
imaging of the diseases such as cardiovascular disorders, obesity, and cancer where macrophages play a patho-
genic role.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Macrophages play a key role in initiating the inﬂammatory and im-
mune responses that often becomes uncontrolled in diseases such as
atherosclerosis, myocardial infarction, obesity, and cancer[1,2]. It has
been shown that the number of inﬂammatory macrophages in athero-
sclerotic plaque correlates with plaque rupture[3]. In obesity, macro-
phages inﬁltrate the adipose tissue during weight gain and contribute
to local and systemic inﬂammation eventually causing insulin resistancelar Medicine, Department of
nited States.
(A. Maiseyeu).
Sinai, York, NY 10029, United
n Jose, CA 95128, United States.
. This is an open access article under(IR) and type 2 diabetes mellitus. Medical imaging and therapeutic
strategies that target tissue macrophages are intensively sought after
due to their signiﬁcant relevance in the etiology of cardiovascular and
metabolic disease. Successful human translation of strategies honed in
mouse models may allow for non-invasive detection of macrophage
burden.
Nanoparticle-based probe delivery systems offer selective and
effective detection of targeted cells. Nanoparticles labeled with imaging
probes are often used for selective macrophage recognition. It is well
established that circulating monocytes, splenic macrophages and
disease-associated macrophages (for example in atherosclerotic plaque
and tumor) rapidly engulf the nanoparticles by virtue of their intrinsic
phagocytic ability[4]. It is clear that macrophage-targeted agents are
well known, however, our ability to selectively image detrimental
(“bad”) macrophages is very limited. New nanoparticle formulations
are needed to overcome the hurdle of cell speciﬁcity manifested inthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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example, many currently available nanoparticles target both anti-
inﬂammatory and pro-inﬂammatory macrophages and tend to be
engulfed by other phagocytic cells such as dendritic cells and neutro-
phils. Time consuming screening studies are sometimes needed to ob-
tain nanoparticle that target to speciﬁc cell population, or to devise
the optimal physicochemical characteristics of the cell-targeted carrier
such as size, charge, and shape[5]. Macrophage-targeted theranostics
currently focus on macrophage reduction strategies such as selective
killing of plaque macrophages by photodynamic therapy (PDT) and
photothermal therapy (PTT) using photosensitizers such as dextran
coated gold nanorods or single walled carbon nanotubes[6]. Although
somewhat effective, such therapies have limited light penetration and
can cause signiﬁcant collateral tissue damage. In contrast, macrophage
selective interventions that deliver small-molecule therapeutics, oligo-
nucleotides or biologics can avoid potential tissue damage, diminish un-
wanted side effects, and provide opportunity to manipulate the cells'
immune response[7].
Our laboratory, among others, has been working on the detection of
inﬂammatory cell populations in experimental disease models such as
atherosclerosis and type 2 diabetes[8–10].We set out to develop a “uni-
versal” nanoparticle probe capable of incorporating a variety of imaging
probes and therapeutic drugs with targeted delivery to M1 macro-
phages. Towards this goal, we turned our attention to commercially
available polystyrene latex as model nanoparticles and ﬁne research
tool. Polystyrene nanoparticles have been used as model nanoparticles
to study mechanism of nanoparticle drug delivery carrier uptake and
processing in macrophages[11–14]. Latex nanoparticles are inexpen-
sive, stable at high salt and protein content, and can be easily modiﬁed
via passive adsorption or covalently bound to biomolecules[15,16].
Importantly, bare latex nanoparticles have been shown to selectively
label inﬂammatory monocytes and macrophages in pathologies such
as atherosclerosis, diabetes, and airway infection though the efﬁciency
was relatively low[17,18].
In this study, we report lipid–latex (LiLa) hybrid nanoparticles
targeting inﬂammatory macrophages. As shown in Fig. 1, the latex
core served as a model hydrophobic polymeric template and the
lipids provided targeting functionality and colloidal stability. Targeting
to inﬂammatory macrophages was achieved by coating LiLa
with phosphatidylserine (PtdSer) and oxidized cholesterol ester deriva-
tive cholesterol-9-carboxynonanoate (9-CCN). These lipids, sometimes
called “eat-me” signals, are efﬁciently phagocytized by macro-
phages[8,19]. We previously used PtdSer and 9-CCN in different nano-
particles to target and image macrophages in atherosclerosis,
however, to our knowledge there are no prior reports of a theranostic
nanocarrier using “eat-me” signals that can accommodate hydrophobic
dye/drug molecules in any combination and size (latex nanoparticles
and spheres are commercially available in sizes from 20 nm to 10 μm).Fig. 1. Schematic illustration of components in LiLa nanoparticles. The single step self-assembl
particles (LiLa). The targeting to macrophages is achieved by phagocytic signals phosphatidylse
or Alexa-647 imaging probes are expected to serve as contrast agents for MRI and ﬂuorescencThis makes LiLa particles truly versatile and suitable for high-
throughput nanoparticle screening. The selectivity of LiLa to image
pro-inﬂammatory macrophages was tested in two disease models:
(i) an experimental atherosclerosis model, where macrophages were
imaged non-invasively through magnetic resonance imaging (MRI)[4,
7]; and (ii) a model of diet induced obesity, where pro-inﬂammatory
macrophages were identiﬁed using intravital ﬂuorescence imaging of
adipose pad. In addition, we tested whether LiLa nanoparticles can
serve as efﬁcient theranostics for inﬂammation. These prototypical
LiLa nanoparticles are schematically depicted in Fig. 1.
2. Results
2.1. Synthesis and characterization of LiLa nanoparticles
LiLa nanoparticles were synthesized through a one-step self-
assembly after hydration of lipid ﬁlm with 4% aqueous polystyrene
latex nanoparticles (40 nm in diameter) followed by fast bath sonica-
tion. All lipid ﬁlms contained 2–5 mol% of PtdSer and 9-CCN, 5 mol%
of phosphatidylethanolamine-PEG2000 and varying concentrations of
contrast agents, drug and dyes (see below and Supporting Information).
We discovered that the lipid ﬁlm may include up to 7 mol% of
hydrophobic entities in any combination, thus allowing for controlled
synthesis of particles with desired functionality (Fig. 1). With the
aim of creating theranostic MRI-visible nanoparticles, that can be
tracked via ﬂuorescence and effectively shorten longitudinal (T1) relax-
ation time, we prepared nanoparticles bearing gadolinium DTPA-
bis(stearylamide) [Gd-DTPA-SA] using ﬂuorescent (FITC) latex core.
The assembly of lipid layer on latex nanoparticleswas tested across a
number of formulations obtained by hydrating 0.2–16 mg of lipid ﬁlm
with 4% of latex nanoparticles for optimal size and stability of LiLa
nanoparticles. As shown in Fig. 2a, dynamic light scattering measure-
ments indicated the formation of larger, heterogeneous particles with
lipid content N1.5 mg, possibly due to the formation of mixed micelles
and large vesicles encapsulating multiple latex cores. A molar ratio of
1.5 mg of lipids per 1 mg of latex provided the best compromise
between size (65 ± 10 nm) and polydispersity (PDI) [0.11 ± 0.05]
for Gd-FITC-LiLa particle formulation (lead formulation). Cryo-
transmission electron microscopy (cryo-TEM) conﬁrmed that Gd-LiLa
particles consisted of a latex core decorated with a lipid-PEG layer, as
seen by the outer corona (white arrowheads on Fig. 2b). The electron-
dense dark spots (yellow arrows on Fig. 2b) seen on the surface of the
latex core most likely indicate the Gd-lipids. The magnetic properties
of Gd-FITC-LiLa longitudinal (T1) relaxation times of protons in water
solutions of Gd-LiLa were measured at a clinically-relevant magnetic
ﬁeld strength of 1.5 T (Fig. 2c). The r1 relaxivity for Gd-FITC-LiLa
(8.3 mM−1 s−1) was 2-fold higher than clinically approved Magnevist
Gd-DTPA (4.0 mM−1 s−1)[20]. The Gd-LiLa formulation was highlyy with a latex core template, lipids, dyes/drugs yields theranostic lipid–latex hybrid nano-
rine (PtdSer) and cholesterol-9-carboxynonanoate (9-CCN). LiLa formulations bearing Gd
e imaging.
Fig. 2. Physicochemical, magnetic and drug-loading properties of LiLa. (a) A relationship
between the concentration of the lipid fraction in LiLa, nanoparticles' size and dispersity.
The hydrodynamic size and polydispersity index (PDI) was measured by DLS for 12
formulations and presented as mean of three replicates ± standard error on double Y-
axis (red, left is size and right, blue is PDI). (b) The cryo-TEMmicrographs ofGd-LiLa nano-
particles. Yellow arrows indicate the electron-dense spots attributed to Gd deposition on
the surface of the latex. White arrows depict prominent PEG corona around the particles.
(c)MRI relaxivity characteristics ofGd-LiLa nanoparticles presented as a function of the re-
laxation times T1 vs gadolinium concentration. T1 values were extracted from the signal
intensity of the corresponding phantoms (inset) after curve ﬁtting using a range of repe-
tition times (seemethods). Themolar relaxivity, r1, was obtained from the slope of T1−1 vs
gadolinium concentration. (d) Drug loading capacity of LiLa as determined on threemodel
hydrophobic drugs: rosiglitazone (Rosi), paclitaxel (PAX) and tamoxifen (TAM). The data
obtained from three different formulations for each drug is presented asmean± standard
error. (e) Plasma stability of Rosi-LiLa as determined by dynamic dialysis against 50%
human plasma at 37 °C.
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bare-latex nanoparticles that appeared turbid immediately aftermixing
with 10% human plasma (Fig. S2). Size measurements of Gd-LiLa andTable 1
Particle size of Gd-Lila formulation.a
Sample Water PBS
Diameter (nm) PDI Diam
Gd-LiLa(0.16 h) 51.28 ± 0.46 0.05 86.
Gd-LiLa (48 h) 53.92 ± 0.23 0.07 49.
Bare-latex(0.16 h) 54.49 ± 0.57 0.07 45.
Bare-latex(48 h) 91.56 ± 0.47 0.23 51.
a Data as mean ± standard deviation (n = 3). Samples in PBS buffer and 10% human serumbare latex in human plasma or PBS have conﬁrmed superior stability
of Gd-LiLa (Table 1).
2.2. Drug loading and release
To determine whether LiLa can incorporate small molecule thera-
peutics along with Gd-DTPA-SA and lipids, we studied Gd-LiLa drug
loading capacity with three model hydrophobic drugs: Rosiglitazone
(Rosi), Paclitaxel (PAX) and tamoxifen (TAM). All the drugs displayed
high binding to LiLa (Fig. 2d and Table S4), with Rosi being the most
efﬁcient (0.59 ± 0.15 mg of drug per 1 mg of latex), whereas PAX and
TAM incorporation was 0.14 ± 0.07 mg and 0.48 ± 0.39 mg of drug
per 1mg of latex respectively (Table S4 in Supplementary Information).
Next, we investigated drug release via dynamic dialysis release experi-
ments using Rosi-LiLa as a model formulation. The release of Rosi from
Rosi-LiLa particles incubated in 50% human plasma for 72 h at 37 °C
was less than 4% (as measured by LC–MS; Fig. 2e).
2.3. LiLa nanoparticles selectively target inﬂammatory M1-macrophages
in vitro
Weaimed to test Gd-FITC-LiLa in human andmouse atherosclerosis-
relevant in vitro systems: 1) murine ﬁbroblast cell line (L-cells),
2) human umbilical vein endothelial cells (HUVECs), and 3) murine
RAW 264.7 macrophages. The Gd-FITC-LiLa was efﬁciently internalized
by macrophages after 4 h of incubation at 37 °C. Fig. 3a illustrates
that the RAW 264.7 macrophages showed high uptake of Gd-LiLa
particles (i.e., 100% of the cells were particle-positive after 4 h) while
L-cells and HUVEC cells were only somewhat efﬁcient in nanoparticle
uptake. The Gd-FITC-LiLa were observed to localize in the lysosomal
compartments of RAW 264.7 cells, but not in lysosomes of L-cells or
HUVECs (Fig. 3a). Co-localization was evident after merging micro-
graphs of Gd-FITC-LiLa ﬂuorescence with that of immunoﬂuorescence
of lysosomal-associated membrane protein 1 (LAMP1). Next, the kinet-
ics of Gd-FITC-LiLa cellular uptake in these cells wasmeasured by quan-
tifying cell ﬂuorescence at various time points using a plate reader
(Fig. 3b). RAW 264.7 cells demonstrated rapid, linear uptake over 24 h
incubation. Conversely, the uptake in L-Cells and HUVECs was blunted
and reached saturation at 8 h.
Next, differential uptake of LiLa bearing AlexaFluor 647 was studied
in two major sub-types of macrophages (M1, M2) using imaging
ﬂow cytometry. M1- and M2-macrophages were prepared using
bone-marrow derived macrophages from wild-type C57BL/6 mice as
previously described[21]. The polarization of the resting macrophages
into the M1 and M2 subtypes following stimulation was conﬁrmed
by measuring the mRNA expression of different markers characteristic
for these phenotypes (Supporting Information, Fig. S4). The results of
ﬂow-cytometric analysis demonstrated that LiLa nanoparticles
were taken up by M1-macrophages more efﬁciently than by M2-
macrophages as seen in the histograms in Fig. 3c and d. The histogram
representing LiLa uptake in M1 macrophages (Fig. 3d, ﬁlled red) is
shifted, indicating increased ﬂuorescence levels in these cells as com-
pared with M2 cells. Conversely, bare latex nanoparticles did not
demonstrate the selectivity in uptake (Fig. 3c). To visualize the uptake
on a single cell level, Amnis FlowSight imaging was used tobuffer 10% human serum
eter (nm) PDI Diameter (nm) PDI
50 ± 3.56 0.2 98.99 ± 4.57 0.39
69 ± 0.41 0.05 75.32 ± 5.15 0.41
36 ± 0.24 0.07 397.40 ± 215.59 0.84
00 ± 1.86 0.13 693.40 ± 416.96 0.49
were incubated at 37 °C.
Fig. 3. In vitro characterization of various LiLa nanoparticles in different cell lines. (a) Confocal microscopywas used to evaluate Gd-FITC-LiLa (green) uptake inﬁbroblasts (L-cells), human
umbilical vein endothelial cells (HUVEC) and macrophages (RAW264.7). The right panel represents the overlay of ﬂuorescent and bright ﬁeld (DIC) micrographs. For visualization of the
lysosomal compartment, cells were stained with antibody against lysosomal-associatedmembrane protein 1 (red). (b) Time-dependent uptake of Gd-LiLa by different cell lines. The data
were normalized to the protein content in cell lysates. The quantiﬁcationwas based on 3–4 independent replicates, and the error bars represent standard deviation. The statistical analysis
of the time-course trend by two-way ANOVA demonstrated a signiﬁcant difference in uptake of Gd-LiLa by RAW cells as compared to HUVEC (p b 0.001) and L-cells (p b 0.01). (c,d) Flow
cytometry analysis of bonemarrow derived macrophages that were polarized to M1 andM2 phenotypes and treated with bare latex or LiLa nanoparticles. The M1 inﬂammatory pheno-
type showed higher uptake of LiLa particles compared toM2phenotype. Single-cell analysis bymeans of imaging ﬂow-cytometry (inset) suggested intracellular localization of LiLa inM1-
macrophages (see text).
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insets). The results demonstrate that the cells incubatedwith bare latex
produce a somewhat diffuse staining, likely due to membrane-
associated particles that were not yet internalized. Similar appearance
of the LiLa staining was noted in M2 macrophages (Fig. 3d, bottom
inset). In contrast, highly localized, punctate staining of LiLa nanoparti-
cles was observed inM1-macrophages (Fig. 3d, middle inset). The latter
could indicate nanoparticle internalization and the accumulation in in-
tracellular compartments, likely in lysosomes, as demonstrated above
in RAW 264.7 macrophages (Fig. 3a). Taken together, these resultsindicate that the M1 macrophages preferentially engulf LiLa nanoparti-
cles, likely through the phagocytic signals that alsomediate rapid intra-
cellular localization[22].
2.4. Anti-inﬂammatory LiLa nanoparticles dampen macrophage
inﬂammation
We next studied whether drug-loaded LiLa is therapeutically active
in vitro by investigating the anti-inﬂammatory effects of Rosi-LiLa in
pro-inﬂammatory macrophages. The RAW 264.7 macrophages were
Fig. 4. Therapeutic properties of rosiglitazone-loaded LiLa (Rosi-LiLa) in an in vitro model
of inﬂammation. (a, b) An in vitro model of inﬂammation was created and evaluated by
ﬂow-cytometry using a marker of inﬂammation lymphocyte antigen 6C (Ly6C) and a
macrophage-speciﬁc antibody F4/80. A treatment of RAW 264.7 macrophages with
lipopolysaccharide (LPS) gave rise to inﬂammatory macrophages, of which 18% were
Ly6C-positive. The control macrophages (buffer-treated) were only 2.5%-positive for
Ly6C. (c, d) Antiinﬂammatory effects of Rosi-LiLa were studied in the inﬂammation
model described above. A treatment of inﬂammatorymacrophageswith Rosi-LiLa resulted
in signiﬁcant reduction of Th1 response with signiﬁcantly attenuated production of indi-
cated cytokines (c) and mRNA transcripts (d). The data are expressed on a logarithmic
scale as percent change in cytokine concentration over concentration in cells treated
with phosphate buffered saline (PBS). The error bars denote standard deviation of three
separate experiments performed in triplicate. t-Test was used to determine signiﬁcance.
*p b 0.05, †p b 0.01 vs. PBS control.
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100 ng/mL lipopolysaccharide (LPS) for 24 h. The M1 phenotype was
conﬁrmed using ﬂow cytometry by surface marker Ly6C immunostain-
ing (Fig. 4a, b). The results show that LPS-stimulated cells demonstrated
signiﬁcantly higher surface expression of Ly6C as compared to
unstimulated cells. The signiﬁcant increase in levels of the pro-
inﬂammatory cytokines (sometimes called Th1 response) such as
TNF-α, IL-6 and CCL-2 in cell culture media of LPS-treatedmacrophages
was also an indicator of “M1”-phenotype (Fig. 4a,b) and (Supporting In-
formation, Fig. S5)[23]. Third, we ensured that concentrations of free
and nanoparticle-bound drug added to the cells were identical
(100 ng/mL) by measuring Rosi concentrations by LC–MS (supporting
information-methods) just before the experiment. After an exposure
of cells to bare latex, free Rosi, and Rosi-LiLa for 4 h, we analyzed apanel of inﬂammation-associated cytokines using BD Biosciences Cyto-
metric Bead Array.We observed a signiﬁcant decrease in the concentra-
tion of the Th1 cytokines (TNF-α, CCL-2, and IL-6) in cells treated with
Rosi-LiLa and Rosi but not bare latex. Rosi-LiLa was as efﬁcient as Rosi
alone in dampening inﬂammation (Fig. 4c). Similar trend was observed
at the transcriptional level with quantitative RT-PCR (Fig. 4d).
2.5. Controlled release of the cargo from LiLa nanoparticles is phospholipase
A2-dependent
LiLa particles are highly stable, possibly due to protective lipid shell
(Fig. 1). At the same time, the phospholipase A2 (PLA2) is known to
rapidly degrade phospholipids, particularly when the phospholipid
shell is presented on nanoparticle surface[24]. We speculated that
latex particles that are devoid of lipid shell will have signiﬁcantly re-
duced stability in physiological environment. To investigate the possi-
bility of PLA2-triggered LiLa degradation, we ﬁrst designed and
synthesized LiLa nanoparticles equipped with Förster resonance energy
transfer (FRET) properties that could be regulated by PLA2. FRET-LiLa
beacon (Fig. 5a) was synthesized from ﬂuorescein-cored latex (FRET
donor) and a model drug rhodamine (FRET acceptor), the latex core
and phospholipid layer. Non-FRET controls were also synthesized and
included: FITC-Lila, where ﬂuorescein is incorporated in the core with-
out lipids, and Rhod-LiLa, where rhodamine dye is absorbed on the
bare latex nanoparticles (without FITC) and coveredwith lipids as usual.
To conﬁrm FRET, the ﬂuorescence spectra of FRET-LiLa in deionized
water or methanol was recorded on a spectroﬂuorometer with a 460-
nm excitation. The FRET-LiLa exhibited a strong 550 nm emission signal
due to the energy transfer from ﬂuorescein to rhodaminewhen present
in close proximity to each other. Methanol decomposition of FRET-LiLa
resulted in FRET loss as detected by a concurrent increase in ﬂuorescein
emission at 480 nmand disappearance of the 550 nmpeak (Fig. 5b).We
then incubated snake-venom PLA2 (Naja mossambica) with FRET-LiLa
or single-ﬂuorophore LiLa particles serving as non-FRET controls.
Fig. 5c demonstrates time course ﬂuorescence response of FRET and
non-FRET beacons monitored at a 480 nm emission using plate reader.
The results show that the PLA2 produced a rapid and saturated FRET
loss response in FRET-LiLa as compared to non-FRET LiLa controls,
indicating the occurrence of enzymatically-triggered rhodamine re-
lease. Slight increase in 480 nm emission from non-FRET rhodamine-
LiLa (Rhod-LiLa)wasdue to, perhaps, the increase inﬂuorescence inten-
sity of the bulk-released rhodamine, which was otherwise locally self-
quenched in LiLa nanoparticles. The intracellular PLA2-mediated drug
release from FRET-LiLa was assessed in macrophages. RAW 264.7
macrophages were pretreated for 24 h with or without 20 μMmethyl
arachidonyl ﬂuorophosphonate (MAFP, an inhibitor of PLA2)[25] and
then incubated with FRET-LiLa nanoparticles for 4 h, followed by
confocal microscopy analysis. To quantify the FRET loss we employed
sensitized emission FRET confocal microscopy for analysis of FRET
efﬁciency and distance (see Supporting Information for method de-
tails)[26]. Fig. 5d and e illustrates an outcome of these measurements
presented as processed FRET (pFRET) micrographs indicating FRET-
positive areas inside of the cells. Cells that were treated with MAFP,
PLA2 inhibitor, were observed to have greater FRET efﬁciency (0.77 vs
0.48) and smaller distance (8.3 nmvs 9.2 nm) as compared to untreated
cells suggesting the detachment of rhodamine from LiLa particles in a
PLA2-dependent manner.
We next investigated the role of phospholipids in the “protection” of
latex-adsorbedmolecules when LiLawas exposed to human serum. The
nanoparticles containing Rhodamine with and without phospholipids
(Rhod-Latex and Rhod-LiLa respectively) were incubated in PBS or
30% human serum at 37 °C, and the ﬂuorescence emission spectra of
rhodamine were recorded over time. It is well known that rhodamine
ﬂuorescence is highly sensitive to self-quenching[27–29]. The spectra
in PBS indicate that the emission intensity of rhodamine is similar in
both formulations and is likely self-quenched due to high local
248 V. Bagalkot et al. / Journal of Controlled Release 217 (2015) 243–255concentration of the rhodamine on the surface of the nanoparticles.
However, when the nanoparticles were subjected to human serum,
Rhod-Latex exhibited a 4.5-fold increase in the ﬂuorescence intensity
as compared to Rhod-LiLa (Fig. 5f). Next, we investigatedwhether “pro-
tective” effect can be reduced when phospholipids are partially degrad-
ed by PLA2. Because it is very difﬁcult to control the enzymatic reaction
to obtain LiLa with partially-degraded phospholipids, we synthesized
Rhod-LysoPC-Latex, where 50% of phosphatidylcholine (PC) in LiLa,
was replaced with Lyso-PC, a product of PLA2 enzymatic activity on PC
(Fig. 5a inset). We incubated Rhod-LysoPC-Latex with human serum
same as in above experiments and recorded ﬂuorescence emission
over time. In contrast to burst release from Rhod-Latex, Rhod-LysoPC-
Latex demonstrated graduate, sustained release of the rhodamine as in-
dicated by steadily increasing emission intensity over time (Fig. 5f).
These results along with FRET data described above indicate that the
protective phospholipid shell is needed for latex-adsorbed molecules
to be carried in physiological environment.2.6. Molecular MRI with Gd-FITC-LiLa detects inﬂammatory macrophages
To test in vivo imaging characteristics of Gd-FITC-LiLa and the ability
to image inﬂammatorymacrophages,we have performedmagnetic res-
onance (MR) imagingwith Gd-LiLa serving as a contrast agent. The test-
ingwas performed in apolipoprotein E knockout mice (ApoE−/−, KO), a
well-known model of inﬂammation and atherosclerosis. Dynamic MR
imaging of Gd-FITC-LiLa nanoparticles enabled sustained visualization
of the vasculature as shown in maximum intensity projection T1-
weighted scans (Fig. 6a). MR images show that contrast-enhanced
blood-pool signal was stable up to 2 h after Gd-FITC-LiLa injection in
WT mice and allowed for identiﬁcation of descending abdominal aorta
(A), celiac trunk (C), superior mesenteric artery (M), and at least one
kidney (K). Importantly, the contrast kinetics suggested signiﬁcantly
prolonged persistence of Gd-FITC-LiLa in the circulation of WT mice
with a half-life of t1/2 = 49 min, as compared to that in KO mice with
t1/2 = 12 min. Fast blood clearance of Gd-FITC-LiLa in KO mice
prompted us to speculate that this is the result of the preferential and
rapid uptake of Gd-LiLa by inﬂammatory monocytes in circulation and
“M1”-like macrophages in major organs. Pharmacokinetic experiments
(Fig. 6b) performed on a separate set (n = 7) of WT and KO mice
injected with Gd-FITC-LiLa conﬁrmed the longer residence time in cir-
culation (t1/2 = 63 min) of Gd-FITC-LiLa in WT mice as compared to
that in KO animals (t1/2 = 13 min).
Further, we also investigated plaque associated macrophage uptake
of Gd-FITC-LiLa nanoparticles by MR imaging of the abdominal aorta
using T1-weighted gradient-echo sequence developed in our
laboratory[8–10]. Gd-FITC-LiLa nanoparticles were injected into KO
andWT animals (n=3–4 per group) followed byMR imaging of the ab-
dominal aorta. Fig. 6c shows axial multiplanar images that demonstrate
prominent Gd-FITC-LiLa accumulation in the vascular wall (arrows) of
KO but not WT animals. Quantitative analysis of contrast enhancement
expressed as a ratio of signal intensity in plaque vs that in muscle con-
ﬁrmed visual observation of MR scans (Supporting Information Fig. S6).
Cell-speciﬁc deposition of Gd-FITC-LiLa in plaque was further evalu-
ated by examining aortic tissue sections by confocal microscopy. Fig. 6d
and e shows representative ﬂuorescence micrographs of aortic tissue
from KO mice injected with Gd-FITC-LiLa. Staining with macrophageFig. 5. Controlled release of the model drug from LiLa nanoparticles. (a) Design of FRET-LiLa be
ducing a FRET pair with excitation λ1 = 460 nm and emission λ3 = 550 nm. Upon cleavage of
resulting in a FRET loss (ﬂuorescein emitting at λ2 = 480 nm). Inset:schematic represen
(b) Fluorescence emission spectra of FRET-LiLa in water (red curve) and methanol (blue curv
formulations after exposure to PLA2. Snake-venom PLA2was simultaneously added to all three
RAW cells in sensitized emission FRET (pFRET) mode before (MAFP−) and after (MAFP+) th
were analyzed) gave rise to FRET efﬁciency and FRET distance of MAFP treated and untreated
recorded in PBS or 30% human serum over time for latex nanoparticles incorporating rhodam
(Rhod-LiLa), and LiLa particles with rhodamine where 50% of phosphatidylcholine was replace
niﬁcance. *p b 0.05.speciﬁc marker F4/80 and nuclear dye DAPI allowed for visualization
of nanoparticles within the macrophages. The merged ﬂuorescence
signal from Gd-FITC-LiLa (green), macrophage speciﬁc marker F4/80
(red) (blue) appeared yellow, indicating strong co-localization between
Gd-FITC-LiLa and macrophages. Conversely, a much smaller number of
Gd-FITC-LiLa nanoparticles in aorta of WT animals were detected.
Consistent with this ﬁnding, there was no observable co-staining of
Gd-FITC-LiLa (green) and macrophage speciﬁc marker F4/80 (red) in
aortic tissue sections of WT mice (Supporting information Fig. S7). In-
terestingly, Gd-FITC-LiLa appeared to deposit to the shoulder of the ath-
erosclerotic lesions in KO mice (Fig. 6d, asterisk).
The biodistribution of Gd-FITC-LiLa nanoparticles indicated a sub-
stantial difference in nanoparticle levels between KO and WT mice
(Supporting information Fig. S8). The intravenously injected Gd-FITC-
LiLa were predominantly taken up by the spleen, liver, aorta and to a
lesser extent in lungs and heart, followed by kidneys and adipose, as
reported for nanoparticles ≤100 nm [30]. Consistent with our imaging
data, the Gd-FITC-LiLa was found at high concentrations in the athero-
sclerotic plaque of KO mice compared to bare latex nanoparticles that
accumulated to a large extent in the liver (supporting information
Fig. S9). In addition, cell-speciﬁc distribution in these tissues was inves-
tigated by immunohistochemistry of tissue sections with F4/80 anti-
body (detecting macrophages) and anti-CD31 antibodies (detecting
endothelial cells). The results show that Gd-FITC-LiLa strongly co-
localized with macrophages (Supporting Information, Fig. S7), but min-
imally in CD31-positive endothelial cells in liver, spleen, aorta, heart,
kidney tissues. Taken together, these results suggest that LiLa nanopar-
ticles preferentially target inﬂammatory “M1” macrophages allowing
for effective imaging of vasculature and atherosclerosis.2.7. LiLa nanoparticles enable intravital near-infrared ﬂuorescence imaging
and selectively accumulate in inﬂammatory macrophages within the adi-
pose tissue
Having demonstrated the utility of Gd-LiLa nanoparticles for selec-
tiveMR imaging of pro-inﬂammatory “M1”macrophages in atheroscle-
rosis, we then turned to explore the scope ofmolecular imaging of these
cells in the adipose tissue.Molecular imaging ofmacrophages in adipose
tissue was performed in a model of diet-induced obesity known to
exhibit visceral adipose inﬂammation. In order to distinguish macro-
phages from other cell types in vivo, we took advantage of reporter
mice where macrophages ubiquitously express the yellow ﬂuorescent
protein (YFP). Adipose tissue imaging was conducted with a time-
lapse single-photon confocal intravital microscope, built in-house on
the basis of the VisiTech Inﬁnity3 system (see Fig. 7a and Supporting
Information for details) and using AlexaFluor 647 nanoparticles
(AF647-LiLa) as a contrast agent. We used obese c-fmsYFP+ mice as a
convenient model of M1-macrophage enriched adipose[31], which
was termed “M1-model” because their adipose tissue best resembles
clinical obesity. Control animals (lean) were termed an “M2-model”,
given the fact that the healthy adipose tissue is populated by macro-
phages with distinct “M2” features[23].
Confocal time-lapse imagingof adipose enabled robust identiﬁcation
ofmacrophages thatwere detected by their intrinsic YFPﬂuorescence at
an excitation of 514 nmand emissionmaxima at 527 nm (Fig. 7b and c).
We then injected AF647-LiLa into our M1- and M2-models andacon: ﬂuorescein incorporated latex core (green) is decorated with rhodamine (red) pro-
phospholipid layer (yellow) with methanol or phospholipase PLA2, rhodamine is released
tation of formation of LysoPC, the product of PLA2-induced phospholipid hydrolysis.
e). (c) FRET-loss was monitored by recording changes in λ2 (480 nm) signal in three LiLa
formulations at 6min of incubation. (d) Confocal ﬂuorescence images of FRET-LiLa-treated
e treatment with PLA2 inhibitor (MAFP). (e) pFRET image analysis (7–10 slides per group
cells. A distance ≥10 nm indicates no FRET. (f) Rhodamine ﬂuorescence emission spectra
ine but no phospholipids (Rhod-Latex), LiLa particles with rhodamine and phospholipids
d with Lyso-phosphatidylcholine (Rhod-LysoPC-Latex). t-Test was used to determine sig-
249V. Bagalkot et al. / Journal of Controlled Release 217 (2015) 243–255monitored the uptake over time. The AF647-LiLa injection produced
bright and stable red ﬂuorescence signal observed in the adipose
blood vessels (Supporting InformationMovie 1). Fig. 7b and c shows im-
ages of the adipose at different time points indicating the uptake of
AF647-LiLa (red) by YFP+-macrophages (green). AF647-LiLa wereobserved to localize at junctions of adipocytes (characteristic
hexagonal-like shaped large cells) and co-localize with YFP+ macro-
phages (arrows, Fig. 7b, c). We observed that macrophages concentrat-
ed particles ~20 min after injection in M1-model, whereas, in M2-
model, the deposition of LiLa was mostly noted in junctions of adipo-
250 V. Bagalkot et al. / Journal of Controlled Release 217 (2015) 243–255cytes, and to the lesser extent in YFP+ cells. The rapid accumulation of
LiLa in inﬂammatory macrophages of M1-model was also observed
through quantitative image analysis. The average of the AF647-LiLa
ﬂuorescence intensity in YFP+ cells for each frame was recorded and a
time vs nanoparticle ﬂuorescence intensity plot was generated
(Fig. 7d). By comparing the area under the curve (AUC) from M1-
model vs M2-model, we determined the relative uptake of AF647-LiLa
by macrophages (“M1” vs “M2”) in the adipose tissue (Fig. 7e). We
also observed that the initial peakﬂuorescence inM1-model was signif-
icantly higher than that in the M2-model.
3. Discussion
We found that latex nanoparticles can be easily decorated with
macrophage targeting phospholipid components phosphatidylserine
(PtdSer) and oxidized cholesterol ester derivative cholesterol-9-
carboxynonanoate (9-CCN) resulting in lipid–latexhybrid nanoparticles
(LiLa), where the latex core served as a model size-determining tem-
plate and lipid/hydrophobic entities provided functionality. These
lipids, sometimes called “eat-me” signals, are efﬁciently phagocytized
by macrophages[9,19]. We previously used PtdSer and 9-CCN in differ-
ent nanoparticles to target and image macrophages in atherosclerosis,
however, to our knowledge there are no prior reports of a theranostic
nanocarrier using “eat-me” signals that can accommodate hydrophobic
dye/drug molecules in any combination and size (latex nanoparticles
and spheres are commercially available in sizes from 20 nm to 10 μm).
This makes LiLa particles truly versatile and a model research tool.
The hydrodynamic diameter of Gd-LiLa was 65 ± 10 nm and
particles were colloidally stable in PBS buffer and 10% human plasmaFig. 6. In vivoMRI, blood clearance andmacrophage targeting characteristics of Gd-FITC-LiLa na
culature in wild type (WT) and atherosclerotic ApoE−/− knockout (KO) animals following injec
dominal aorta (A), celiac trunk (C), superior mesenteric artery (M), and kidney (K). (b) Th
concentration of Gd in blood over time by inductively coupled plasma mass spectrometry. The
the standard deviation of biological replicates. (c) A representative T1-weighted gradient echoM
wall (arrows) inWT and KOmice before and 24 h after Gd-FITC-LiLa injection. Prominent contra
mice 24 h post Gd-FITC-LiLa injection. (d, e) Confocal microscopy micrographs of atherosclero
shoulders of atherosclerotic plaque (asterisks) was observed in overlaid DIC and ﬂuorescence i
calized with ﬂuorescence of Gd-FITC-LiLa (green) and was seen as yellow on micrographs of a
with DAPI.at 37 °C as compared to bare latex nanoparticles (Table 1 and Figs. S1–
S2). It is well documented that nanoparticle size determines in vivo
pharmacokinetics with nanoparticles spanning a range of sizes from
50 to 100 nm being the most favorable for tissue penetration after sys-
temic administration[32]. Therefore; we selected this Gd-FITC-LiLa as
“lead” formulation for all future studies. We observed two fold higher
r1 relaxivity for Gd-FITC-LiLa as compared to a commercial agent
Magnevist, which is likely due to the result of reduced tumbling rate
resulting from anchoring of Gd chelates to the external surface of the
latex and the consequent increase in rotational correlation time of the
bound contrast agent[33]. The dynamic dialysis experiments of Rosi-
LiLa in 50% human plasma showed less than 4% release at 72 h at
37 °C (Fig. 2e). These results indicate that theranostic LiLa nanoparticles
can stably carry drug payloads in physiological environment and thus
act as highly efﬁcient, controlled drug delivery carriers.
The drug loading efﬁciency of Rosi was the highest as compared to
tamoxifen (TAM) and paclitaxel (PAX) due to positive charge of the
Rosi molecule carrying an aminopyridine fragment (Fig. 2, Table S4).
We speculate that slightly positive charge of Rosi allows higher loading
due to electrostatic interaction with the negatively charged latex nano-
particles. Similar effect is often observed for positively charged doxoru-
bicin, known to exhibit superior loading when encapsulated within
negatively charged nanomaterials[34]. Paclitaxel is known to have
decreased stability in aqueous solutions and mixture of aqueous and
organic solvents. The relatively low stability of paclitaxel may have con-
tributed to its minimal loading on LiLa particles[35].
We believe that all molecules and probes used in LiLa are
“sandwiched” between the latex core and the phospholipid shell. The
latter serves as an outer “protective” layer along with PEG (that is alsonoparticles. (a) Representative time-lapsemagnetic resonance imaging (MRI) scans of vas-
tion of Gd-FITC-LiLa. The early time-point images show high contrast enhancement in ab-
e Gd-FITC-LiLa blood clearance in WT and KO mice was determined by measuring the
data presented are from seven mice (n = 4 KO and n = 3 WT) and the error represents
R scan in the axial plane (right) and the correspondingmagniﬁcations depicting the aortic
st-enhanced delineation of the aorticwall is clearly seen as bight hyperintense signal in KO
tic plaque of KO mice treated with Gd-FITC-LiLa. (d) The accumulation of Gd-FITC-LiLa in
mages at 20× magniﬁcation. (e). The signal from F4/80-positive (red) macrophages co-lo-
therosclerotic plaque at 60× magniﬁcation. Nuclei (blue) were detected through staining
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assumptions are based on two lines of evidence and existing literature
on polymer–lipid hybrid nanoparticles. First, our cryo-TEM investiga-
tion led us to believe that phospholipids are presented via monolayer
on the surface sub-100 nm latex, similar to PLGA- or silica-based
hybrids that are frequently used for drug delivery by research groups
of R. Langer, O. Farokhzad and others[36–38], and have been shown to
have distinct phospholipid monolayer[36–38]. Given the similarity of
LiLa to these nanosystems in terms of size and composition, and our
DLS and cryo-TEM investigations, we are conﬁdent that LiLa is covered
by a monolayer of phospholipids.
Second, when the nanoparticles containing rhodamine with and
without phospholipids were incubated in 30% human plasma, the
presence of phospholipid shell in Rhod-LiLa prevented dye leakage
even after 2 h of incubation. The stability of the system was drastically
decreased when PC phospholipids were replaced with lyso-PC.
Lysophospholipids are known to serve as detergents disrupting
phospholipid membranes, change organization of phospholipids in
the membrane, and tilt hydrophobic chains allowing for facilitated
exchange between inner membrane and outer membrane molecules.
Having demonstrated preferential uptake of LiLa nanoparticles by
macrophages (Fig. 3a, b), we next tested the possibility of differential
uptake of LiLa between two major sub-types of macrophages. The role
of a macrophage in a tissue is largely governed by the polarization
state, which determines the pro- or anti-inﬂammatory and phagocytic
potential. Macrophage polarization is likely a continuous scale, while
the extremes in polarization are well characteristic[23]. Thus, bone
marrow- or peritoneal-derived macrophages stimulated with LPS are
referred to as M1-phenotype and characterized by a high expressionFig. 7. In vivo confocal imagingwith LiLa nanoparticles. (a) Schematic view of a confocal micros
and then reﬂected into a galvanometer scanner (galvo) by the dichroic mirror. The laser beam
emitted light is then “descanned” back to the galvanometer allowing for synchronized imaging
adipose pad. (b, c) Representative time-lapse confocal images of the adipose tissue in M1 and
yellow ﬂuorescent protein (YFP) reporter mice were injected with AF647-LiLa nanoparticles an
(green) and AF647-LiLa (red) over time. (d) Quantiﬁcation of mean ﬂuorescence intensity of A
series were analyzed with ImageJ software by selecting YFP+ region of interest in each fram
(e) Area under the curve (AUC) was calculated to determine the rate of uptake of AF647-LiLa ilevel of pro-inﬂammatory molecules such as iNOS, TNF-α, and IL-6. In
contrast, M2 macrophages are prepared via stimulation with IL-4 and
express high levels of CD206 and Arginase-1 (Arg-1). While the process
of macrophage phenotyping is an ongoing debate, it is well recognized
that M1-like macrophages potentiate inﬂammatory processes in
diseases of such as atherosclerosis and obesity. Therefore, we next in-
vestigated whether the uptake of LiLa nanoparticles differs in M1- and
M2-polarized macrophages. The results from imaging ﬂow cytometry
studies show that LiLa particles are engulfed to a higher extent in M1
macrophages, and demonstrate a distinct punctate accumulation
pattern indicating lysosomal localization within M1 macrophages
(Fig. 3c, d).
LiLa nanoparticles can serve as efﬁcient vehicles for intracellular de-
livery of therapeutics as indicated by our experiments in RAW 264.7
macrophages after treatment with bare-latex, free drug Rosi and Rosi-
LiLa nanoparticles (Fig. 4). We chose Rosiglitazone (Rosi) as a model
drug, as it is a high-potency peroxisome proliferator-activated receptor
(PPAR) γ agonist with anti-inﬂammatory effects [39]. Although, Rosi
suffers from severe side effects, including weight gain and congestive
heart failure and was recently withdrawn from clinical use[40]. It is,
however, a powerful model drug routinely used in diabetes and obesity
research, that is able to modulate inﬂammatory and immune responses
inmacrophages and trigger fast changes in gene expression[41–43]. The
results showed a signiﬁcant decrease in the concentration of the Th1
cytokines (TNF-α, CCL-2, and IL-6) in cells treated with Rosi-LiLa and
free Rosi. However, we reason that free Rosi and Rosi-LiLa, although
taken up by in macrophages through a different pathways (passive dif-
fusion for free drug versus receptor-mediateduptake for Rosi-LiLa), pro-
vide similar functional effect due to 1) identical amount of Rosi used incope used for intravital imaging of adipose. A laser light is focused through a pinhole array,
is then used to scan the sample through galvanometer as it moves across the image. The
with minimal distortion. A live imaging is performed through a small incision in animal's
M2 mouse models of adipose inﬂammation. “M1” (obese, n = 3) and “M2” (lean, n = 3)
d subjected to intravital imagingmonitoring ﬂuorescence signals from YFP+macrophages
F647 (expressed as % of maximum ﬂuorescence) in YFP+ macrophages over time. Image
e, followed by analysis of average ﬂuorescence intensity of AF647 for each time point
n macrophages. t-Test ⁎p b 0.01 M1-model vs M2-model.
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and 2) possible saturation of the binding site of the nuclear receptor at
the concentration of Rosi used in this study. This resulted in almost
identical changes in downregulation of inﬂammatory gene expression.
It is somewhat surprising that Rosi-LiLa nanoparticles eluting b4% of
their payload over 72 h (Fig. 2e) show a pronounced anti-inﬂammatory
effects in macrophages after 4 h of incubation (Fig. 4). Therefore, we
asked the question: how do LiLa nanoparticles release their cargo
when engulfed by the cell? It has been suggested that nanoparticles
with the polymeric core incorporating hydrophobic drugs and “decorat-
ed” with phospholipid exterior layer have increased stability and
delayed drug release[44]. On the other hand, the rate of the degradation
of phospholipids by phospholipases increases signiﬁcantly when the
phospholipid layer is presented on the surface of nanoparticles[24].
We, therefore, investigated whether the drug release mechanism from
LiLa nanoparticles is facilitated by intracellular phospholipases.
Phospholipase A2 (PLA2) is known to be signiﬁcantly upregulated in in-
ﬂammatory macrophages and found at high concentrations in
atherosclerosis[45–48]. The results show that the PLA2 produced a
rapid and saturated FRET loss response in FRET-LiLa as compared to
non-FRET LiLa controls, indicating the occurrence of enzymatically-
triggered rhodamine release (Fig. 5c). The intracellular FRET efﬁciency
measurements in macrophages after addition of PLA2 inhibitor indicate
greater FRET efﬁciency and smaller distance as compared to untreated
cells. These results show that enhanced activity of PLA2 towards
phospholipid layer on the LiLa surface may result in facilitated drug re-
lease, whichmanifests in therapeutic actions of Rosi-LiLa demonstrated
in Fig. 4.
It is well established that “M1”-like macrophages are present
in progressing atherosclerotic plaques[23] and that their numbers
may increase drastically as a result of plaque-inﬁltrating inﬂammatory
Ly6Chigh monocytes, especially in response to hyperglycemia[49], myo-
cardial infarction[50], and stress[51]. These cells are characterized by
high phagocytic capacity demonstrating progressive uptake of lipids
and oxidized lipoproteins, which becomes more pronounced in
progressing atherosclerosis[23,52]. Conversely, “M2”-macrophages are
highly-efﬁcient during their homeostatic role in clearing apoptotic
cells (in theprocess called efferocytosis), but becomephagocytically im-
paired in progressing atherosclerotic plaques[53]. Here, we reasoned
that “M1”-macrophages and Ly6Chigh monocytes, being intrinsically
more efﬁcient phagocytes when compared to other cells in advanced
atherosclerosis, can be selectively discerned by hyper-uptake of Gd-
LiLa in MRI, allowing for “molecular imaging”. To test this hypothesis
in vivo, we have chosen a well-validated animal model of atherosclero-
sis, apolipoprotein E knockout mice (ApoE−/−, KO). The deletion of
ApoE gene transcripts in mice not only provides a useful preclinical
model of atherosclerosis with features similar to human disease[54],
but also gives rise to macrophages that are ubiquitously skewed to an
“M1”-phenotype[55,56].
Macrophage targeted molecular dynamic MR imaging and pharma-
cokinetic experiments showed that Gd-LiLa particles decreased half-life
in KO mice as compared with WT controls. The fast clearance from
circulation could likely be attributed to uptake by the inﬂammatory
monocytes in circulation and “M1”-like macrophages in major organs.
It is well known that nanoparticles with a diameter of sub-100 nm pen-
etrate “leaky” vasculature and become accessible for macrophages in
sub-endothelial space[32]. We further investigated whether Gd-LiLa
can deposit in plaque-associated macrophages allowing non-invasive
imaging of abdominal aorta. MRI scans demonstrated prominent Gd-
LiLa accumulation in the vascular wall (Fig. 6c). This result was also
conﬁrmed by ex vivo immunohistochemistry of aortic sections by
confocal microscopy, that showed colocalization of Gd-LiLa and macro-
phage marker F4/80. We found that Gd-LiLa appeared to deposit to the
shoulder of the atherosclerotic lesions in KOmice (Fig. 6d, asterisk). It is
well known that the shoulder region of plaque is extensively inﬁltrated
by macrophages and characterized by increased inﬂammation andshear stress, also being the sitewhere plaque rupture ismost commonly
observed[57].
The biodistribution of Gd-LiLa nanoparticles studied by LC−MS
showed that Gd and Rosi were detected at high concentration in the
plaque, demonstrating the drug delivery capability of LiLa (Supporting
information Fig. S8). Immunohistochemistry of tissue sections also
conﬁrmed the preferential targeting of LiLa nanoparticles to macro-
phages in the liver, spleen, aorta andminimal presence in lungs, kidneys
in KO mice (Supporting information Fig. S7). The biodistribution study
demonstrated that two key tissues of interest (atherosclerotic aorta
and fatty adipose) can be selectively targeted by LiLa particles because
of the presence of M1macrophages. We also observed some accumula-
tion in lungs (Fig. S8). Interestingly, the lung tissue of KO mice were
targeted by LiLa-NPs, as compared to minimal targeting in WT mice.
We also posited that lipid and PEG layer on LiLa may decrease lung
deposition as compared to bare latex or other NPs such as silica NPs.
Thus, in a study by Z. Fayad and colleagues it was shown that silica
NPs signiﬁcantly deposited to lungs due to aggregation, whereas
PEGylated silica–lipid hybrid NPs showed minimal lung uptake[58].
The speciﬁcity of LiLa to “M1”-macrophages in plaque and other tissues
may still have to be conﬁrmed, however, this is beyond the scope of this
proof-of-principle study. We also envision that the rapid-clearance of
Gd-LiLa may provide superior intravascular MR enhancement and
reduced toxicity[59].
Although adipocytes are the major cell type that constitutes healthy
adipose tissue, macrophages are found at increased numbers in the
visceral fat depots of obese humans andmice[60].Macrophage polariza-
tion plays a critical role in initiation and progression of obesity and
comorbidities such as metabolic disease (insulin resistance). Metabolic
abnormalities caused by obesity have been shown to polarize adipose
tissue macrophages from an “M2” to an “M1” phenotype inducing
inﬂammation via Th1-type pro-inﬂammatory cytokines[23,61]. Molec-
ular imaging of “M1”-cells in obesity may allow non-invasive assess-
ment of adipose tissue inﬂammation and identify individuals at risk
for insulin resistance. To perform adipose tissue imaging, we have pre-
viously demonstrated that c-fmsYFP+ mice on an FVBN background
are characterized by stable and selective expression of YFP in Ly6Chigh
F4/80+ leukocytes, the precursors of pro-inﬂammatory “M1”-macro-
phages in the adipose[31,62]. Due to intrinsic bright YFP ﬂuorescence
these cells can be conveniently detected using intravital microscopy in
living animals. Adipose tissue imaging conﬁrmed the accumulation of
AlexaFluor 647 nanoparticles (AF647-LiLa) at junctions of adipocytes
(characteristic hexagonal-like shaped large cells) and co-localized
with YFP+ macrophages and a higher accumulation was observed in
M1 model compared to M2 model showing the uptake of AF647-LiLa
as a function of macrophage phenotype (Fig. 7).
Taken together, these data support use of LiLa nanoparticles as a
model research tool for intravital imaging. Early time-point imaging
data (b10 min after injection) indicate that LiLa nanoparticles allow
for clear visualization of the adipose vascular system, a property that
might be useful for imaging of other highly vascular sites such as
neovascularized tumors[63]. Most importantly, our data show that the
model LiLa nanoparticles target subsets of macrophages effectively by
exploiting differential phagocytic ability among macrophage pheno-
types (M1, M2) with avid accumulation of “eat-me” signal-containing
LiLa nanoparticles by inﬂammatory adipose macrophages. This opens
the possibility of further developing LiLa-like nanoparticles with
biocompatible polymers as novel agents for “molecular imaging” of obe-
sity and obesity-related chronic diseases.
4. Conclusions
The goals of this study were: 1) to develop a simple, yet versatile
multifunctional theranostic platform using readily available latex core
as a model polymer and a ﬁne research tool to assemble latex-lipid
nanohybrids that could be synthesized in any laboratory and that met
253V. Bagalkot et al. / Journal of Controlled Release 217 (2015) 243–255the drug delivery needs of the research community who might lack
nanoparticle expertise or access to sophisticated manufacturing
facilities; and 2) to demonstrate that phagocytic “eat-me” signals can
preferentially target inﬂammatory macrophages in experimental
models of atherosclerosis and adipose tissue inﬂammation opening
the possibility of future clinical applications that diagnose/treat these
conditions. We acknowledge that due to poor biodegradability of poly-
styrene, LiLa nanoparticles are unlikely to pass regulatory requirements
for clinical translation. We believe, however, that principles of phago-
cytic targeting employed here can be generalized to any other biocom-
patible and biodegradable nanoparticles including those on “fast-track”
for clinical translation[32,64]. Our results suggest that the LiLa platform
is a promising theranostic nanosystemwith potential use in a myriad of
research and pre-clinical endeavors focusing on novel therapies,
targeting ligands or imaging approaches, rather than developing new
drug delivery platform(s). The phagocytic targeting may be impactful
in diseases where macrophage inﬂammation has pathophysiological
relevance including cardiovascular disease, obesity, diabetes, and
cancer. A highly exciting prospect with immediate clinical implications
lies in “molecular imaging” through radiotracer phagocytic signals, a
possibility that warrants future exploration.
5. Methods
5.1. Synthesis of LiLa nanoparticles
9.43mg (12.0 μmol) of L-α-phosphatidylcholine, 2.43mg (3.0 μmol)
of 1,2-dioleoyl-sn-glycero-3-phospho-L-serine, 4.64 mg (12.0 μmol) of
9-CCN and 3.31 mg (3.0 μmol) of Gd-DTPA-SA were mixed in chloro-
form and evaporated to dryness under nitrogen stream. The resulting
lipid ﬁlm was hydrated with 500 μL of 2 wt.% carboxylate modiﬁed
latex particles (either ﬂuorescein- or dark red/AlexaFluor647-cored
from Life Technologies) and subjected to water-bath ultrasonication
usingMisonix Sonicator 3000 for 10min at room temperature to obtain
gadolinium lipid–latex nanoparticles (Gd-FITC-LiLa).
5.2. Drug loading, encapsulation and loading efﬁciencies
To load the LiLa particles with hydrophobic drugs, the solutions of
rosiglitazone (Rosi), tamoxifen (TAM), and paclitaxel (PAX), all at
1 mg/mL in methanol, were introduced to the lipid component, evapo-
rated under nitrogen, and hydrated with latex nanoparticles as de-
scribed above. Drug-LiLa nanoparticles were than puriﬁed by
exhaustive dialysis against running tap deionized water using dialysis
tubing with MW cutoff of 50 kDa (Sigma-Aldrich), and additionally by
size-extrusion chromatography using 7 k MWCO Zeba centrifuge col-
umns (Thermo-Pierce). To analyze the amount of drug remained in
LiLa after puriﬁcation, 100 μL of nanoparticles were vigorously mixed
with 240 μL of methanol plus 10 μL of 1 μg/mL of internal standard in
methanol (Tolbutamide analytical standard VETRANAL, Fluka), after
which the precipitated polystyrenewas separated by high-speed centri-
fugation (15 min × 25,000 g) and supernatant was collected in a sepa-
rate tube. The polystyrene pellet was subjected to extraction with
methanol in the same manner for three more times (total 4 × 250 μL
methanol), following which combined extracts were evaporated
under nitrogen gas, and the residue was reconstituted in HPLC mobile
phase (acetonitrile:water 75:25). Analysis of drug concentration was
next performed by LC–MS as described in Supporting Information.
Drug concentrations were quantiﬁed with a standard curve. Peak
areas were normalized to the spiked internal standard (Tolbutamide)
to standardize between LC–MS runs and to account for deviation in
extraction efﬁciency. The drug encapsulation (EE) and loading (LE) efﬁ-
ciencies were calculated using following equations: EE (%) = [total
weight of drug in LiLa] / [weight of drug initially added] × 100%; LE
(%) = [total weight of drug in LiLa] / [total weight of latex used] × 100%.5.3. Drug release tests
The release of rosiglitazone (Rosi) from Gd-Rosi-LiLa was evaluated
using a combination of dialysis and ultracentrifugal precipitation,which
ensures separation of the proteins from nanoparticles. Thus, 100 μL of
Gd-Rosi-LiLa in PBS at 500 μg Rosi per 1 mg polystyrene was mixed
with 400 μL of 50% human plasma and immediately distributed into
dialysis chambers of eight Sigma Dispo-Biodialyzers (50 μL each).
Dispo-Biodialyzers were then immersed into a beaker containing
250 mL of preheated to 37 °C 50% human plasma with stirring at
120 rpm. At the predetermined time point (1, 2, 4, 12, 24 and 72 h)
one Dispo-Biodialyzer was removed and the sample was collected via
centrifugation as per manufacturer's instructions. The sample was
then diluted with 950 μL of PBS and placed into an ultracentrifuge
tube (Thermo). Next, the sample was ultracentrifuged in a Sorvall
TFT-80.2 rotor at 50,000 g for 1 h using Sorvall WX100 ultracentrifuge.
The pelleted nanoparticles were then resuspended in 1 mL PBS via
sonication, and ultracentrifugation was repeated. Each LiLa formulation
at each time point was washed twice using ultracentrifugal precipita-
tion as described above. The concentration of Rosi was measured in
the pellet of LiLa after drug extraction with methanol in the presence
of internal standard (see above) followed by LC–MS analysis
(Supporting Information). The cumulative release percentage of Rosi
from LiLa at each time point was calculated as: Rosi released (%) =
(1− [total weight of Rosi in precipitate] / [total weight of Rosi in Gd-
Rosi-LiLa]) × 100%.
5.4. In vitro experiments
5.4.1. Uptake of LiLa nanoparticles and visualization with confocal
microscopy
Cells were seeded on glass coverslips 24 h before use. After treat-
ment with 2 μL/mL of LiLa, the cells were washed three times with
PBS, ﬁxed with 4% formaldehyde for 10 min, and then permeabilized
with 0.2% Triton X-100 for 5 min. Filamentous actin was labeled with
AlexaFluor-546 phalloidin (Invitrogen) for 30 min according to
manufacturer's instructions. For LAMP1 immunostaining, the cells
were treated with various LiLa as mentioned above and in the text,
ﬁxed, permeabilized, blocked with 5% BSA in PBS for 1 h at room tem-
perature, and incubated with rabbit anti-mouse LAMP1 primary anti-
body (Abcam) overnight at 4 °C. After washing extensively with PBS,
the cells were incubated for 2 h at room temperature with donkey
anti-rabbit AlexaFluor 647 secondary antibody (Life Technologies). All
secondary antibody incubations were performed in the dark to mini-
mize photo bleaching. The cells were then washed extensively in PBS,
stained with DAPI (Life Technologies) for 10 min, and mounted on
glass slides with Prolong Gold reagent (Life Technologies). The stained
cells were imaged on an Olympus FV1000 spectral confocal microscope
using 60× objective.
5.4.2. Therapeutic potential of LiLa nanoparticles
RAW 264.7 cells were cultured in two 24-well plates according to
conditions described above. One plate was treated with 100 ng/mL
LPS and the second plate was left untreated. After 24 h of incubation,
both plates were washed with sterile PBS three times and fresh media
was added. Next, 1 μL of concentration-adjusted Rosi-LiLa, Rosi alone,
or bare latex (ﬁnal concentration 100 ng/mL of Rosi, except bare
latex) was added in both plates in quadruplicates. Four wells in each
plate were left nanoparticle-free. Both plates were incubated for 4 h
and then washed with PBS. Fresh media was added, and incubation
was continued until the next day. After incubation, the media was
collected and stored at−80 °C until analysis via Inﬂammation 6-Plex
Kit (see below). The cells were lysed using the lysis buffer supplied
with Agilent RNAMiniprep Kit and the lysates were used for RNA isola-
tion followed by quantitative real-time PCR analysis (Supporting
Information).
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Inﬂammatory cytokines were measured in cell media using mouse
Inﬂammation 6-Plex Kit from BD Bioscience (San Diego, CA) according
to manufacturer's instructions.
5.4.4. PLA2-triggered drug release kinetic experiments
One microliter of FRET-LiLa or control particles (FITC-LiLa, Rhod-
LiLa) was mixed in a well of 96-well opaque microplate (6 wells per
particle type) containing 99 μL of 100 mM sodium acetate buffer
(pH = 4.5), 0.5 mM calcium chloride and 0.1% bovine serum albumin.
Plate was equilibrated at 37 °C for 20 min in the cell culture incubator,
sealed with PCR-grade adhesive ﬁlm and placed into 37 °C-preheated
tray of Perkin Elmer Victor 3 ﬂuorescence plate reader. Fluorescence
measurements using 450nmexcitationﬁlter and 480nmemissionﬁlter
were registered every 2min for 6min and then 20 μL of enzyme solution
in PBS containing 0.15 U/mL (~2 ng) PLA2 (Sigma-Aldrich P7778) was
injected in each well and measurements were continued for thirty
more minutes. Fluorescence intensity data was averaged for each parti-
cle type and datawere presented as a % increase in 480nmﬂuorescence.
5.5. Animals
All animalworkwas performed inAAALAC accredited facilities provid-
ed by TheOhio State University Laboratory Animal Resources (ULAR). The
Institutional Animal Care and Use Committee (IACUC) approved the
experimental animal protocols. Ten male ApoE−/− (KO) and six male
C57BL/6 (WT)micewere obtained from Jackson Laboratories (BarHarbor,
ME). All KO animals were placed on a high-fat/high-cholesterol diet (0.2%
total cholesterol, 42% calories from fat; Harlan Teklad, Madison, WI) ad
libitumbeginning at 15weeksuntil 45weeks of age. c-fmsYFP+ transgenic
mice were generated at the Transgenic Animal Service of Queensland,
Brisbane, Queensland, Australia (www.tasq.uq.edu.au) by injection of the
transgenes into pronuclei of (C57BL/6 × CBA)F1 (BCBF1) fertilized
eggs as previously described [55]. YFP+ were fed normal chow diet
(M2-model, n = 3) or high fat diet for 15 weeks (M1-model, n = 3).
5.6. Magnetic resonance imaging
MRIwas performed as previously described [10,11]. Brieﬂy;MRI scans
were performed using an 11.7 T Bruker MRI System (Billerica, MA, USA).
Mice (n = 10 ApoE−/− and n = 6WT) were anesthetized with inhaled
isoﬂurane/O2 gas mixture (maintenance: 1.5–2% of isoﬂurane) delivered
through a nose cone and ﬁxed head-up with paper tape in a 32 mm
transmit/receive birdcage coil. A respiratory sensor was placed on the
abdomen to monitor the depth and frequency of respiration to adjust
the depth of anesthesia. A rectal probe monitored body temperature.
After localization and acquisition of the pre contrast scan, each mouse
was taken out of the magnet and injected with 100 μL of Gd-LiLa (0.1
mmol/kg of Gd) via penile vein injection and immediately placed back
in themagnet for the post contrast scans. Eachmousewas imaged for ap-
proximately 2h after contrast administration using repetitive acquisitions
of the 3D FLASH spin echo sequence. After the last 3D FLASH MRI scan,
each mouse was taken out of the coil and kept in a quarantine facility
for 24 h. After that, MRI scans were repeated using gradient echo
sequence to image abdominal aortas as previously described [10,11].
5.7. Time-lapse confocal imaging of adipose pad
The diagram of the confocal microscope set-up used for real-time
in vivo imaging of inﬂamed adipose is shown of Fig. 6a. The system
was equipped with Olympus inverted microscope, Visitech Inﬁnity 2D
array confocal system (Sunderland, United Kingdom), and electron
multiplying charge-coupled device (EMCCD, Hamamatsu, Hamamatsu
Photonics, Japan). The basic optical path consisted of a stationary
micro-lens array illuminated with an expanded laser beam. A galva-
nometer mirror scans the array over the sample and de-scans thereturningﬂuorescence light. This light is separated from the illuminating
beam by a dichroicmirror, and passes through a stationary pinhole array
to create the confocal image. This image is re-scanned in perfect
synchronization by the reverse side of the galvanometer mirror onto
an EMCCD camera. The galvanometer scanner is readily synchronized
to the selected camera exposure time and frame capture rate. All
sequential images were obtained at 25 frames/s with the exposure
time of 100 ms for each image. The Visitech system was equipped with
an argon laser for excitation at 514 nm, and the emission signal was
collected using a multidichroic mirror and 520 and 647 nm band-pass
ﬁlters. Long Working Distance M Plan Semi-Apochromat (LMPLFLN)
Olympus object lens (×20 air) with numerical aperture 0.40 was used
to visualize YFP+ macrophages and AF647-LiLa+ cells in adipose tissue.
5.8. Statistical analysis
Data are presented as the mean ± SD. Statistical analysis was per-
formed using paired t-test for comparisons within groups. MRI data
were analyzed using repeated measure two-way analyses of variance
(ANOVA). Statistical signiﬁcance was established at p b 0.05.
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